Last reviewed · How we verify

Subacute Stent Thrombosis Prevention — Treatment Landscape & Competitive Intelligence

Subacute Stent Thrombosis Prevention (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Subacute Stent Thrombosis Prevention, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Iopidine APRACLONIDINE Harrow Health alpha-Adrenergic Agonist Alpha-2A adrenergic receptor 1987-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. · 1 drug in Subacute Stent Thrombosis Prevention
  2. Harrow Health · 1 drug in Subacute Stent Thrombosis Prevention

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Subacute Stent Thrombosis Prevention:

Cite this brief

Drug Landscape (2026). Subacute Stent Thrombosis Prevention — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/subacute-stent-thrombosis-prevention. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing